Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis

Background: Tixagevimab/cilgavimab (TGM/CGM) are neutralizing monoclonal antibodies (mAbs) directed against different epitopes of the receptor-binding domain of the SARS-CoV-2 spike protein that have been considered as pre-exposure prophylaxis (PrEP). Objectives: This study seeks to assess the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhumaid, Saad, Al Mutair, Abbas, Alali, Jalal, Al Dossary, Nourah, Albattat, Sami Hussain, Al HajjiMohammed, Sarah Mahmoud, Almuaiweed, Fatimah Saad, AlZaid, Maryam Radhi, Alomran, Mohammed Jaber, Alqurini, Zainab Sabri, Alsultan, Ahmed Abduljalil, Alhajji, Thamer Saeed, Alshaikhnasir, Sukainah Mohammad, Al motared, Ali, Al mutared, Koblan M., Hajissa, Khalid, Rabaan, Ali A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777759/
https://www.ncbi.nlm.nih.gov/pubmed/36547204
http://dx.doi.org/10.3390/diseases10040118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777759/
https://www.ncbi.nlm.nih.gov/pubmed/36547204
http://dx.doi.org/10.3390/diseases10040118

Ejemplares similares